Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04254107 · ClinicalTrials.gov registry record · Phase 1
A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer
A Phase 1 study, sponsored by Seagen.
- Terminated
- Registry status
- Phase 1
- Development phase
- 133
- Enrollment target
NCT04254107 is a Phase 1 study that was terminated before completion, run by Seagen. The registered enrollment target is 133 participants.
The verdict
NCT04254107, a Phase 1 study, was terminated before completion, sponsored by Seagen.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 133 participants
- Enrollment target
Study Summary
This trial will look at a drug called SEA-TGT (also known as SGN-TGT) to find out whether it is safe for patients with solid tumors and lymphomas. It will study SEA-TGT to find out what its side effects are. A side effect is anything the drug does besides treating cancer. It will also study whether SEA-TGT works to treat solid tumors and lymphomas. The study will have four parts. Part A of the study will find out how much SEA-TGT should be given to patients. Part B will use the dose found in Part A to find out how safe SEA-TGT is and if it works to treat solid tumors and lymphomas. Part C will study how well SEA-TGT with sasanlimab works to treat solid tumors. Part D will study how well SEA-TGT with brentuximab vedotin works to treat classical Hodgkin lymphoma (cHL).
Interventions
- DRUG brentuximab vedotin
- DRUG sasanlimab
- DRUG SEA-TGT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 133 participants |
| Start Date | 2020-05-29 |
| Est. Completion | 2023-12-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04254107
The ClinicalTrials.gov registry entry for NCT04254107 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 133 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seagen, which has 84 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which brentuximab vedotin is the first listed.
NCT04254107 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04254107 about?
NCT04254107 is a clinical study titled "A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer". This trial will look at a drug called SEA-TGT (also known as SGN-TGT) to find out whether it is safe for patients with solid tumors and lymphomas. It will study SEA-TGT to find out what its side effects are. A side effect is anything the drug does besides treating cancer. It will also study whether ...
What is the current status of trial NCT04254107?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 133 participants. The study started on 2020-05-29. Estimated completion is 2023-12-01.
What interventions are being tested in trial NCT04254107?
The interventions under investigation include: brentuximab vedotin (DRUG), sasanlimab (DRUG), SEA-TGT (DRUG).
Who is sponsoring clinical trial NCT04254107?
This trial is sponsored by Seagen, which has 84 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.